To quantify Nectin‐4 expression in tumour lesions using the Nectin‐4‐binding peptide Gallium‐68‐N188 and positron emission tomography (PET)/computed tomography (CT) in patients with advanced or metastasised urothelial cancer eligible for therapy with the Nectin‐4‐directed antibody–drug conjugate enfortumab vedotin, in combination with checkpoint inhibitor pembrolizumab (Ev/P). Here, NECTIN4 is linked to neoplasm.